Sanofi (SNY) presented an overview today of Phase II and Phase III clinical trials for its...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi (SNY) presented an overview today of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine, QIV. Three clinical trials have been conducted to evaluate the safety and the immune response to the vaccine, which SNY says is the next evolutionary stage in protecting against influenza B, a significant cause of influenza illness and associated complications across all ages, and especially children.